CCO Treatment Updates
Attacking the Signal at the Switch: Unraveling the Mysteries of mTOR Inhibition in Multiple Tumor Types
What Is the Rationale for Exploring mTOR Inhibition? |
Module 1 of 5 |
|
Program Director: Jose Baselga, MD
|
|
George Thomas, Jr., PhD, describes the molecular biology of the mTOR signaling pathway and explains its significance in the development and treatment of cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the genetic and molecular characteristics of mTOR
- Discuss the activity of mTOR in growth factor signaling
- Identify signaling pathway defects in specific tumor types that may result in mTOR activation
- Identify mTOR inhibitors currently under clinical study and summarize their mechanisms of action
|
Confirming the Role of mTORs in Oncology: Treatment of Renal Cell Carcinoma |
Module 2 of 5 |
|
Program Director: Jose Baselga, MD
- Robert A. Figlin, MD, FACP
|
|
|
Robert A. Figlin, MD, FACP, examines the rationale for use of mTOR inhibitors in RCC and reviews clinical trial data on these agents’ efficacy and tolerability.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the relationship between mTOR and the pathogenesis of renal cell carcinoma (RCC)
- Discuss the role of PTEN in the development of RCC
- Cite current data from clinical trials evaluating temsirolimus and everolimus for treating patients with RCC
- Describe current therapies recommendations for systemic treatment of advanced RCC
|
mTOR Inhibition in Solid Tumors: Emerging Data and Ongoing Trials |
Module 3 of 5 |
|
CME Program Director: Jose Baselga, MD
|
|
Matthew Kulke, MD, reviews recent clinical trial data regarding the use of mTOR inhibitors in solid tumors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Distinguish the rationale for the use of mTOR inhibition in the treatment of solid tumors
- Discuss recent clinical trial results regarding the activity of mTOR inhibitors in solid tumors, including breast, colorectal, endometrial, neuroendocrine, and sarcoma
- Describe the toxicity profiles of mTOR inhibitors, as observed in recent trials
- Cite ongoing clinical trials of mTOR inhibitors in the treatment of solid tumors
|
Clinical Application in Hematologic Malignancies: Potential of mTOR Inhibitors |
Module 4 of 5 |
|
Program Director: Jose Baselga, MD
- Francis J. Giles, MD, MRCPI, FRCPath
|
|
|
Frank Giles, MD, explores the use of mTOR inhibitors in the treatment of leukemias and lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the rationale for mTOR inhibition as a therapeutic strategy in the treatment of lymphomas and leukemias
- Cite preclinical evidence supporting the clinical exploration of mTOR inhibitors in the treatment of leukemias and lymphomas
- Discuss recent trial results of mTOR inhibitors in the treatment of leukemias and lymphomas
|
mTOR Inhibitors in Practice: Clinical Implications and Future Considerations |
Module 5 of 5 |
|
Program Director: Jose Baselga, MD
|
|
Manuel Hidalgo, MD, PhD, discusses the role of mammalian target of rapamycin (mTOR) inhibitors in treating patients with cancer, both as monotherapy and in combination regimens. Relevant findings from recent and ongoing clinical trials are evaluated.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the role of mammalian targets of rapamycin (mTOR) inhibitors in treating patients with advanced cancer
- Discuss the recommended dosing of mTOR inhibitors for treating patients with cancer
- Describe the toxicities associated with mTOR inhibitors and management strategies of these events
- Cite current data from clinical trials assessing mTOR inhibitors as monotherapy and in combination regimens for treating patients with cancer
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|